SRC and colorectal carcinoma: Furthermore, we performed a detailed assessment of potential SL interactions in colorectal cancer (CRC) and demonstrated that SRC, along with its inhibitor dasatinib, could serve as a potential SL partner for mutations in the WNT signaling pathway.